Paul M Lantos1, John A Branda2, Joel C Boggan3, Saumil M Chudgar3, Elizabeth A Wilson4, Felicia Ruffin5, Vance Fowler5, Paul G Auwaerter6, Lise E Nigrovic7. 1. Divisions of Pediatric Infectious Diseases General Internal Medicine. 2. Department of Pathology, Massachusetts General Hospital. 3. General Internal Medicine. 4. Department of Pediatrics, Duke University Medical Center, Durham, North Carolina. 5. Infectious Diseases. 6. Division of Infectious Diseases, Johns Hopkins Medical Institutions, Baltimore, Maryland. 7. Division of Emergency Medicine, Boston Children's Hospital, Massachusetts.
Abstract
BACKGROUND: Lyme disease is diagnosed by 2-tiered serologic testing in patients with a compatible clinical illness, but the significance of positive test results in low-prevalence regions has not been investigated. METHODS: We reviewed the medical records of patients who tested positive for Lyme disease with standardized 2-tiered serologic testing between 2005 and 2010 at a single hospital system in a region with little endemic Lyme disease. Based on clinical findings, we calculated the positive predictive value of Lyme disease serology. Next, we reviewed the outcome of serologic testing in patients with select clinical syndromes compatible with disseminated Lyme disease (arthritis, cranial neuropathy, or meningitis). RESULTS: During the 6-year study period 4723 patients were tested for Lyme disease, but only 76 (1.6%) had positive results by established laboratory criteria. Among 70 seropositive patients whose medical records were available for review, 12 (17%; 95% confidence interval, 9%-28%) were found to have Lyme disease (6 with documented travel to endemic regions). During the same time period, 297 patients with a clinical illness compatible with disseminated Lyme disease underwent 2-tiered serologic testing. Six of them (2%; 95% confidence interval, 0.7%-4.3%) were seropositive, 3 with documented travel and 1 who had an alternative diagnosis that explained the clinical findings. CONCLUSIONS: In this low-prevalence cohort, fewer than 20% of positive Lyme disease tests are obtained from patients with clinically likely Lyme disease. Positive Lyme disease test results may have little diagnostic value in this setting.
BACKGROUND:Lyme disease is diagnosed by 2-tiered serologic testing in patients with a compatible clinical illness, but the significance of positive test results in low-prevalence regions has not been investigated. METHODS: We reviewed the medical records of patients who tested positive for Lyme disease with standardized 2-tiered serologic testing between 2005 and 2010 at a single hospital system in a region with little endemic Lyme disease. Based on clinical findings, we calculated the positive predictive value of Lyme disease serology. Next, we reviewed the outcome of serologic testing in patients with select clinical syndromes compatible with disseminated Lyme disease (arthritis, cranial neuropathy, or meningitis). RESULTS: During the 6-year study period 4723 patients were tested for Lyme disease, but only 76 (1.6%) had positive results by established laboratory criteria. Among 70 seropositive patients whose medical records were available for review, 12 (17%; 95% confidence interval, 9%-28%) were found to have Lyme disease (6 with documented travel to endemic regions). During the same time period, 297 patients with a clinical illness compatible with disseminated Lyme disease underwent 2-tiered serologic testing. Six of them (2%; 95% confidence interval, 0.7%-4.3%) were seropositive, 3 with documented travel and 1 who had an alternative diagnosis that explained the clinical findings. CONCLUSIONS: In this low-prevalence cohort, fewer than 20% of positive Lyme disease tests are obtained from patients with clinically likely Lyme disease. Positive Lyme disease test results may have little diagnostic value in this setting.
Authors: Andrew M Fine; John S Brownstein; Lise E Nigrovic; Amir A Kimia; Karen L Olson; Amy D Thompson; Kenneth D Mandl Journal: Arch Pediatr Adolesc Med Date: 2011-01
Authors: Julia K Deanehan; Amir A Kimia; Sharman P Tan Tanny; Matthew D Milewski; Paul G Talusan; Brian G Smith; Lise E Nigrovic Journal: Pediatrics Date: 2013-02-18 Impact factor: 7.124
Authors: Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone Journal: Arthritis Rheum Date: 2008-01
Authors: Julia K Deanehan; Peter A Nigrovic; Matthew D Milewski; Sharman P Tan Tanny; Amir A Kimia; Brian G Smith; Lise E Nigrovic Journal: Pediatr Emerg Care Date: 2014-01 Impact factor: 1.454
Authors: Ian R C Davis; Shelly A McNeil; Wanda Allen; Donna MacKinnon-Cameron; L Robbin Lindsay; Katarina Bernat; Antonia Dibernardo; Jason J LeBlanc; Todd F Hatchette Journal: J Clin Microbiol Date: 2020-06-24 Impact factor: 5.948
Authors: Nathan Peiffer-Smadja; Adeline Bauvois; Marie Chilles; Baptiste Gramont; Redwan Maatoug; Marie Bismut; Camille Thorey; Eric Oziol; Thomas Hanslik Journal: J Gen Intern Med Date: 2019-06-12 Impact factor: 5.128